BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ward MG, Thwaites PA, Beswick L, Hogg J, Rosella G, Van Langenberg D, Reynolds J, Gibson PR, Sparrow MP. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Aliment Pharmacol Ther 2017;45:1135-45. [PMID: 28239869 DOI: 10.1111/apt.13992] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Samaan M, Campbell S, Cunningham G, Tamilarasan AG, Irving PM, McCartney S. Biologic therapies for Crohn's disease: optimising the old and maximising the new. F1000Res 2019;8:F1000 Faculty Rev-1210. [PMID: 31448080 DOI: 10.12688/f1000research.18902.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
2 Jasurda JS, McCabe RP, Vaughn BP. Adalimumab Concentration Changes After Dose Escalation in Inflammatory Bowel Disease. Ther Drug Monit 2021;43:645-51. [PMID: 33346627 DOI: 10.1097/FTD.0000000000000849] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Nakase H, Motoya S, Matsumoto T, Watanabe K, Hisamatsu T, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther 2017;46:873-82. [PMID: 28884856 DOI: 10.1111/apt.14318] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 8.8] [Reference Citation Analysis]
4 Wright EK, Kamm MA, De Cruz P, Hamilton AL, Selvaraj F, Princen F, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Jakobovits SL, Florin TH, Gibson PR, Debinski H, Macrae FA, Samuel D, Kronborg I, Radford-smith G, Gearry RB, Selby W, Bell SJ, Brown SJ, Connell WR. Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn’s Disease. Journal of Crohn's and Colitis 2018;12:653-61. [DOI: 10.1093/ecco-jcc/jjy003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
5 Berends SE, Bloem K, de Vries A, Schaap T, Rispens T, Strik AS, Talwar R, Löwenberg M, D'Haens GR, Mathôt RA. Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples. Ther Drug Monit 2020;42:289-94. [PMID: 31464823 DOI: 10.1097/FTD.0000000000000686] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
6 Vande Casteele N, Feagan BG, Wolf DC, Pop A, Yassine M, Horst SN, Ritter TE, Sandborn WJ. Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice. Inflamm Bowel Dis 2021;27:1346-55. [PMID: 33051647 DOI: 10.1093/ibd/izaa265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Ungar B, Engel T, Yablecovitch D, Lahat A, Lang A, Avidan B, Har-noy O, Carter D, Levhar N, Selinger L, Neuman S, Natour OH, Yavzori M, Fudim E, Picard O, Kopylov U, Chowers Y, Naftali T, Broide E, Shachar E, Eliakim R, Ben-horin S. Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and drug concentrations: the POETIC Study. American Journal of Gastroenterology 2018;113:890-8. [DOI: 10.1038/s41395-018-0073-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
8 Park SH, Aniwan S, Loftus EV. Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease. Current Opinion in Pharmacology 2017;37:65-71. [DOI: 10.1016/j.coph.2017.09.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
9 Vande Casteele N, Baert F, Bian S, Dreesen E, Compernolle G, Van Assche G, Ferrante M, Vermeire S, Gils A. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study. J Crohns Colitis 2019;13:1248-56. [PMID: 30820530 DOI: 10.1093/ecco-jcc/jjz050] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
10 Lucafò M, Curci D, Bramuzzo M, Alvisi P, Martelossi S, Silvestri T, Guastalla V, Labriola F, Stocco G, Decorti G. Serum Adalimumab Levels After Induction Are Associated With Long-Term Remission in Children With Inflammatory Bowel Disease. Front Pediatr 2021;9:646671. [PMID: 34017806 DOI: 10.3389/fped.2021.646671] [Reference Citation Analysis]
11 Liefferinckx C, Bottieau J, Toubeau JF, Thomas D, Rahier JF, Louis E, Baert F, Dewint P, Pouillon L, Lambrecht G, Vallée F, Vermeire S, Bossuyt P, Franchimont D. Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021:izab042. [PMID: 33783494 DOI: 10.1093/ibd/izab042] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gibson DJ, Ward MG, Rentsch C, Friedman AB, Taylor KM, Sparrow MP, Gibson PR. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2020;51:612-28. [DOI: 10.1111/apt.15643] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
13 Sirmai L, Pelletier AL, Gault N, Zallot C, Bouguen G, Bouchard D, Roland Nicaise P, Peyneau M, Sironneau S, Bittencourt MDC, Petitcollin A, Fernandez P, Roblin X, Siproudhis L, Abramowitz L. Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study. World J Gastroenterol 2022; 28(9): 961-972 [DOI: 10.3748/wjg.v28.i9.961] [Reference Citation Analysis]
14 Kato M, Sugimoto K, Ikeya K, Takano R, Matsuura A, Miyazu T, Ishida N, Tamura S, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Hanai H. Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease. PLoS One 2021;16:e0254548. [PMID: 34242369 DOI: 10.1371/journal.pone.0254548] [Reference Citation Analysis]
15 Park SH, Al-bawardy B, Aniwan S, Kane SV, Coelho-prabhu N, Papadakis KA, Kisiel JB, Bruining DH, Faubion WA, Raffals LE, Pardi DS, Tremaine WJ, Stephens MC, Tung J, Khanna S, Willrich MAV, Loftus EV. Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360 2019;1:otz047. [DOI: 10.1093/crocol/otz047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Little RD, Chu IE, van der Zanden EP, Flanagan E, Bell SJ, Gibson PR, Sparrow MP, Shelton E, Connor SJ, Roblin X, Ward MG. Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis. J Crohns Colitis 2019;13:1527-36. [PMID: 31094417 DOI: 10.1093/ecco-jcc/jjz103] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Gonczi L, Kurti Z, Rutka M, Vegh Z, Farkas K, Lovasz BD, Golovics PA, Gecse KB, Szalay B, Molnar T, Lakatos PL. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.BMC Gastroenterol. 2017;17:97. [PMID: 28789636 DOI: 10.1186/s12876-017-0654-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
18 Pinto Pais I, Espinheira MC, Trindade E, Amil Dias J. Optimizing Antitumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease With Therapeutic Drug Monitoring. J Pediatr Gastroenterol Nutr 2020;71:12-8. [PMID: 32142005 DOI: 10.1097/MPG.0000000000002704] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;46:1037-53. [PMID: 29027257 DOI: 10.1111/apt.14368] [Cited by in Crossref: 144] [Cited by in F6Publishing: 117] [Article Influence: 28.8] [Reference Citation Analysis]
20 Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 2022. [PMID: 34988877 DOI: 10.1007/s12325-021-01990-6] [Reference Citation Analysis]
21 . Inflammatory Bowel Disease Clinical. Journal of Gastroenterology and Hepatology 2017;32:121-54. [DOI: 10.1111/jgh.13895] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
22 Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR, Irving PM. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. Aliment Pharmacol Ther 2017;46:150-61. [PMID: 28481014 DOI: 10.1111/apt.14124] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
23 Rocha C, Afonso J, Lago P, Arroja B, Vieira AI, Dias CC, Magro F. Accuracy of the new rapid test for monitoring adalimumab levels. Therap Adv Gastroenterol 2019;12:1756284819828238. [PMID: 30833984 DOI: 10.1177/1756284819828238] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Flanagan E, Gibson PR, Wright EK, Moore GT, Sparrow MP, Connell W, Kamm MA, Begun J, Christensen B, De Cruz P, Shelton E, Dowling D, Andrews JM, Brown SJ, Niewiadomski O, Ward MG, Rosella O, Rosella G, Kiburg KV, Ross AL, Bell SJ; PICCOLO Study Group. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther 2020;52:1551-62. [PMID: 32981127 DOI: 10.1111/apt.16102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
25 Lee SD, Shivashankar R, Quirk D, Zhang H, Telliez JB, Andrews J, Marren A, Mukherjee A, Loftus EV Jr. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. J Clin Gastroenterol 2021;55:195-206. [PMID: 32740098 DOI: 10.1097/MCG.0000000000001396] [Reference Citation Analysis]
26 Vande Casteele N, Gils A. Editorial: variability in adalimumab trough and peak serum concentrations. Aliment Pharmacol Ther 2017;45:1475-6. [DOI: 10.1111/apt.14049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
27 Carlsen A, Omdal R, Karlsen L, Kvaløy JT, Aabakken L, Steinsbø Ø, Bolstad N, Warren D, Lundin KEA, Grimstad T. Determination of lower cut-off levels of adalimumab associated with biochemical remission in Crohn's disease. JGH Open 2020;4:410-6. [PMID: 32514446 DOI: 10.1002/jgh3.12266] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Samaan MA, Arkir Z, Ahmad T, Irving PM. Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science? Expert Opin Biol Ther 2018;18:1271-9. [PMID: 30339466 DOI: 10.1080/14712598.2018.1537367] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
29 Samaan MA, Cunningham G, Tamilarasan AG, Beltran L, Pavlidis P, Ray S, Mawdsley J, Anderson SH, Sanderson JD, Arkir Z, Irving PM. Therapeutic thresholds for golimumab serum concentrations during induction and maintenance therapy in ulcerative colitis: results from the GO-LEVEL study. Aliment Pharmacol Ther 2020;52:292-302. [PMID: 32506695 DOI: 10.1111/apt.15808] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]